VTRO (Vitro Biopharma) Total Liabilities: $5.74 Mil (As of Oct. 2022)


What is Vitro Biopharma Total Liabilities?

Vitro Biopharma VTRO Total Liabilities is $5.74 Mil as of Oct. 2022. The stock has 6 warning signs investors should review.

Vitro Biopharma's Total Liabilities for the quarter that ended in Oct. 2022 was $5.74 Mil.

Vitro Biopharma's quarterly Total Liabilities increased from Oct. 2017 ($3.30 Mil) to Oct. 2021 ($7.68 Mil) but then declined from Oct. 2021 ($7.68 Mil) to Oct. 2022 ($5.74 Mil).

Vitro Biopharma's annual Total Liabilities increased from Oct. 2017 ($3.30 Mil) to Oct. 2021 ($7.68 Mil) but then declined from Oct. 2021 ($7.68 Mil) to Oct. 2022 ($5.74 Mil).

Vitro Biopharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma Total Liabilities Chart

Vitro Biopharma Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.27 2.50 3.30 7.68 5.74

Vitro Biopharma Quarterly Data
Oct00 Oct01 Oct02 Oct03 Oct04 Oct05 Oct06 Oct07 Oct08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.27 2.50 3.30 7.68 5.74

Vitro Biopharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vitro Biopharma's Total Liabilities for the fiscal year that ended in Oct. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.54+(2.976+0.222
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.74

Total Liabilities=Total Assets (A: Oct. 2022 )-Total Equity (A: Oct. 2022 )
=8.574-2.836
=5.74

Vitro Biopharma's Total Liabilities for the quarter that ended in Oct. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.54+(2.976+0.222
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.74

Total Liabilities=Total Assets (Q: Oct. 2022 )-Total Equity (Q: Oct. 2022 )
=8.574-2.836
=5.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $5.74 Mil mean?
Vitro Biopharma (VTRO) has a Total Liabilities of $5.74 Mil as of Oct. 2022. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vitro Biopharma and its competitors.
Is Vitro Biopharma's Total Liabilities too high?
Vitro Biopharma's current Total Liabilities is $5.74 Mil.
How does Vitro Biopharma's Total Liabilities compare to ?
Vitro Biopharma's Total Liabilities of $5.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vitro Biopharma and its competitors. Vitro Biopharma's current Total Liabilities is $5.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current Total Liabilities of $5.74 Mil. The current Total Liabilities is $5.74 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current Total Liabilities is $5.74 Mil as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Comparable Companies
Address 4621 Technology Drive, Golden, CO, USA, 80403
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.